MRG-003
- Generic Name
- MRG-003
- Drug Type
- Biotech
- Background
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 106
- Registration Number
- NCT06959108
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05751512
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
- Conditions
- Advanced or Metastatic Gastroesophageal Junction CarcinomaAdvanced or Metastatic Gastric Cancer
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05188209
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Henan Tumor Hospital, Zhengzhou, Henan, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT05126719
- Locations
- 🇨🇳
Zhongshan City People's Hospital, Zhongshan, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
- Conditions
- Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04868162
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of MRG003 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04868344
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04838548
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04838964
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Bethune First Hospital of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.